Abstract
ABSTRACT: The safety of lorazepam was compared with that of a standard drug, glutethimide, in 50 chronically ill geriatric patients. Repeated physical examinations, laboratory determinations and other tests indicated that any organic disease in these patients had become stabilized before the study and was not affected by the test drugs. Early morning drowsiness, dizziness and lethargy were noted with each drug during the first and second weeks. More patients in the glutethimide series discontinued therapy because of side effects than in the lorazepam series. Dosage reduction to 1 mg nightly was necessary in many of those treated with lorazepam. Lorazepam is useful for aiding elderly patients to sleep. The initial dosage should be 1 mg nightly. If necessary, this dosage usually can be increased with safety to 2 mg nightly.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
